Publications

1. GVS advice lenacapavir (Sunlenca®) for the treatment of HIV-1 infection

   The National Health Care Institute advises the Minister to include lenacapavir (Sunlenca®) on List 1B of the Medicine ...

   Report | 22-09-2022

2. Package advice on pegcetacoplan (Aspaveli®) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH)

   The National Health Care Insititute has completed its assessment whether pegcetacoplan (Aspaveli®) can be included in the basic ...

   Report | 16-09-2022

3. Package advice brexucabtagene autoleucel (Tecartus®) refractory mantle cell lymphoma

   The National Health Care Institute advises the Minister not to include brexucabtagene autoleucel (Tecartus®) in the basic health ...

   Report | 09-09-2022

4. Package advice sacituzumab govitecan (Trodelvy®) for the treatment of inoperable or metastasized triple-negative breast cancer

   The National Health Care Institute advises the Minister to include sacituzumab govitecan (Trodelvy®) in the basic health care ...

   Report | 29-07-2022

5. GVS advice testosterone undecanoate (Nebido®)

   The National Health Care Institute advises the Minister to include finerenon (Kerendia®) in List 1B of the GVS. Finerenon is ...

   Report | 21-07-2022

6. Package advice risdiplam (Evrysdi®) for the treatment of 5q spinal muscular atrophy (SMA)

   The National Health Care Institute advises the Minister to include risdiplam (Evrysdi®) in the health insurance package for the ...

   Report | 15-07-2022

7. GVS advice setmelanotide (Imcivree®)

   The National Health Care Institute advises the Minister to include setmelanotide (Imcivree®) in List 1B of the GVS. Setmelanotide ...

   Report | 08-07-2022

8. GVS advice metreleptin (Myalepta®)

   The National Health Care Institute advises the Minister to include metreleptin (Myalepta®) in List 1B of the GVS. Metreleptin is ...

   Report | 08-07-2022

9. GVS advice bempedoic acid (Nilemdo®) for use in adults with primary hypercholesterolaemia or mixed dyslipidaemia

   The National Health Care Institute has completed its assessment whether bempedoic acid is interchangeable with another medicinal ...

   Report | 05-07-2022

10. GVS advice cannabidiol (Epidyolex®) as adjuvant treatment for 2 epileptic disorders

    The National Health Care Institute advises the Minister only to include cannabidiol (Epidyolex®) on List 1B of the Medicine ...

    Report | 04-07-2022